DDInter1927 DDInter1376
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Venlafaxine {u} (Compound) resembles {v} (Compound) Tramadol
Venlafaxine {u} (Compound) resembles {v} (Compound) Desvenlafaxine
Venlafaxine {u} (Compound) binds {v} (Gene) NPY1R
Venlafaxine {u} (Compound) palliates {v} (Disease) panic disorder
Venlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Venlafaxine {u} (Compound) causes {v} (Side Effect) Yawning
Venlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Venlafaxine {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Venlafaxine (Compound) resembles Tramadol (Compound)
Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Venlafaxine (Compound) binds NPY1R (Gene)
Venlafaxine (Compound) palliates panic disorder (Disease)
Venlafaxine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Venlafaxine (Compound) causes Yawning (Side Effect)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine